Solid Dosage
GEA supplies solutions for manufacturing inhalable and oral antiviral drugs ranging from blending, spray drying and particle engineering to continuous manufacturing.
Antiviral medications help the body to fight off harmful viruses such as influenza, chickenpox and the human immunodeficiency virus (HIV), to name a few. The drugs can ease symptoms and shorten the length of a viral infection. Antivirals also lower the risk of getting or spreading viruses that cause herpes and HIV. One approved antiviral treats the coronavirus that causes COVID-19.
Antiviral drugs are also preventive. They can protect you from getting viral infections or spreading a virus to others. They come in many formats, including tablets, intravenous solutions, liquids and inhaled powders.
For inhalable versions, GEA understands that homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.
And, with the ongoing development of oral anti-viral medications, particularly as a result of the COVID-19, pandemic, there is increased interest in the use of continuous manufacturing to accelerate process design and product optimization.
For example, the compact and fully integrated ConsiGma®4.0 platform has been designed to transfer powder into coated tablets in a shorter time frame. Plus, by combining Quality by Design (QbD) principles with Design of Experiments (DoE), it enables operators to explore the design space in a quick and easy way and expedite time-to-market.
يتم عرض 4 من 26
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
At GEA, we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product lifecycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
يعد تقليل النفايات أمرًا مهمًا بالنسبة لنا في GEA، ومن خلال الاستفادة من قوة تكنولوجيا التجفيف بالتجميد، يمكننا تحويل فائض الطعام إلى منتجات قيِّمة وطويلة الأمد - مما يساعد على تقليل النفايات وإطالة العمر الافتراضي للمنتجات وبناء إمدادات غذائية أكثر مرونة للأجيال القادمة.
كان خبراء البحث والتطوير في GEA على قدر التحدي عندما طرحت Pulmuone، وهي شركة كورية جنوبية متخصصة في إنتاج الأغذية النباتية، تحديًا لـ GEA يتمثل في إضفاء لمسة حديثة على النودلز الكورية الباردة التقليدية ذات القوام الواضح في الفم (النينجميون). وساعدوا في تطوير ما أصبح الآن نجاحًا تجاريًا يتم إنتاجه باستخدام كميات أقل من المياه والكهرباء مقارنةً بالطرق المستخدمة سابقًا. وتتوافق النتيجة أيضًا مع الأصول التقليدية للطبق بالإضافة إلى جذور Pulmuone في الصحة والعافية والاستدامة.